Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study.

Alessandra OlivaL LiguoriS CovinoF PetrucciF Cogliati-DezzaA CurtoloG SavelloniM ComiF SaccoG CeccarelliA ViscidoF AlessandriG RaponiF PuglieseC M MastroianniM Venditti

Published in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2024)

CFDC could represent an effective and safe treatment option for CRAB BSI, especially in patients with bacteremic HAP/VAP and frail patients where the risk of acute renal failure during therapy should be avoided.

Keyphrases

acinetobacter baumannii
multidrug resistant
drug resistant
sars cov
coronavirus disease
systematic review
pseudomonas aeruginosa
newly diagnosed
liver failure
cystic fibrosis
patient reported outcomes
acute respiratory distress syndrome
extracorporeal membrane oxygenation
patient reported
community dwelling